ADC Therapeutics CFO granted 271,600 shares

ADC Therapeutics SA Chief Financial Officer Jose Carmona reported equity-related transactions in company common shares.

Rhea-AI Filing Summary

ADC Therapeutics SA Chief Financial Officer Jose Carmona reported equity-related transactions in company common shares. He was granted 271,600 common shares at $3.99 per share as part of a restricted share unit award that vests in three equal annual installments starting on February 13, 2027, contingent on continued service. To cover tax withholding from the vesting of previously granted restricted share units, 25,880 common shares were withheld by the company at $3.99 per share. After these transactions, Carmona directly holds 734,376 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Carmona Jose

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	271,600	$3.99	$1.08M
Exercise Price or Tax Liability	Common Shares	25,880	$3.99	$103K

Holdings After Transaction: Common Shares — 734,376 shares (Direct)

Footnotes (2)

1. F1. Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.
2. F2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADC Therapeutics (ADCT) CFO Jose Carmona report?

Jose Carmona reported an equity grant and related tax withholding. He received 271,600 common shares through a restricted share unit award and had 25,880 shares withheld to satisfy tax obligations tied to earlier restricted share unit vesting.

How many ADC Therapeutics (ADCT) shares were granted to the CFO in this Form 4?

The CFO was granted 271,600 common shares. These shares relate to a restricted share unit award that will deliver shares over three years, subject to one-third vesting each year and continued service through the designated vesting dates.

What is the vesting schedule of Jose Carmona’s new ADC Therapeutics (ADCT) award?

The award vests in three equal annual installments. One-third vests on the first anniversary of the February 13, 2026 grant date, with additional one-third portions vesting on each of the next two anniversaries, conditioned on continued service at each vesting date.

Why were 25,880 ADC Therapeutics (ADCT) shares disposed of in the CFO’s Form 4?

The 25,880 shares were withheld by ADC Therapeutics to cover tax withholding obligations. These obligations arose from the vesting of restricted share units previously granted to the CFO, rather than from an open-market sale of shares.

How many ADC Therapeutics (ADCT) shares does CFO Jose Carmona own after these transactions?

Following the reported grant and tax withholding, the CFO directly owns 734,376 common shares. This figure reflects his updated direct ownership after receiving 271,600 shares and having 25,880 shares withheld to satisfy tax-related obligations.

What transaction codes appear in ADC Therapeutics (ADCT) CFO’s latest Form 4?

The Form 4 shows code A for an award or other acquisition and code F for tax-withholding disposition. Code A corresponds to the 271,600-share grant, while code F covers 25,880 shares withheld to satisfy tax obligations on prior awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 05:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carmona Jose

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/13/2026		A		271,600(1)	A	$3.99	760,256	D
Common Shares	02/13/2026		F		25,880(2)	D	$3.99	734,376	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Jose Carmona	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.